Pathways for small molecule delivery to the central nervous system across the blood-brain barrier

Perspectives in Medicinal Chemistry

Volumn , Issue 6, 2014, Pages 11-24

  Mikitsh, John L ^a   Chacko, Ann Marie ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Pennsylvania   (United States)

Author keywords

Blood brain barrier (BBB); Brain delivery; CNS drug; Facilitated transport; Passive diffusion; Reflux pumps

Indexed keywords

ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHEMICAL PARAMETERS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TARGETING; DRUG UPTAKE; EFFLUX BARRIER; ENZYMATIC BARRIER; HUMAN; HYDROGEN BOND; LIPOPHILICITY; MEMBRANE PERMEABILITY; MOLECULAR FLEXIBILITY; MOLECULAR WEIGHT; NEUROIMAGING; NEUROLOGIC DISEASE; NON INVASIVE PROCEDURE; NONHUMAN; PASSIVE TRANSPORT; PERMEABILITY BARRIER; PHOSPHOLIPID MEMBRANE; PHYSICAL CHEMISTRY; STRUCTURE BARRIER; SURFACE PROPERTY; TREATMENT OUTCOME;

EID: 84902590637     PISSN: None     EISSN: 1177391X     Source Type: Journal    
DOI: 10.4137/PMc.s13384     Document Type: Article

References (98)

1. Chacko AM, Li C, Pryma DA, Brem S, Coukos G, Muzykantov V. Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv. 2013;10(7):907-26.
2. WHO. Neurological Disorders: Public Health Challenges. Geneva, Switzerland: World Health Organization, WHO Press; 2006.
3. Funk M, Drew N, Freeman M, Faydi E. Mental Health and Development: Targeting People with Mental Health Conditions as A Vulnerable Group. Geneva, Switzerland: World Health Organization; 2010.
4. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
5. Furuse M, Itoh M, Hirase T, et al. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol. 1994;127(6 pt 1):1617-26.
6. Fanning AS, Anderson JM. Protein-protein interactions: PDZ domain networks. Curr Biol. 1996;6(11):1385-8.
7. Ballabh P, Braun A, Nedergaard M. Te blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1-13.
8. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1(3):223-36.
9. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41-53.
10. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006;58(2):140-61.
11. Roux F, Durieu-Trautmann O, Chaverot N, et al. Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol. 1994;159(1):101-13.
12. Meyer J, Rauh J, Galla HJ. Te susceptibility of cerebral endothelial cells to astroglial induction of blood-brain barrier enzymes depends on their prolifera-tive state. J Neurochem. 1991;57(6):1971-7.
13. Ghersi-Egea JF, Perrin R, Leininger-Muller B, et al. Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem Pharmacol. 1993;45(3):647-58.
14. Yee RE, Huang SC, Stout DB, et al. Nigrostriatal reduction of aromatic l-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations. J Neurochem. 2000;74(3):1147-57.
15. Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS. Coordinated nuclear receptor regulation of the reflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J Cereb Blood Flow Metab. 2008;28(6):1222-34.
16. Ghersi-Egea JF, Minn A, Siest G. A new aspect of the protective functions of the blood-brain barrier: activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sci. 1988;42(24):2515-23.
17. Miksys S, Tyndale RF. Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci. 2013;38(3):152-63.
18. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug reflux transporters. Nat Rev Neurosci. 2005;6(8):591-602.
19. Loscher W, Potschka H. Blood-brain barrier active reflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86-98.
20. Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ter. 2009;123(1):80-104.
21. Bendayan R, Ronaldson PT, Gingras D, Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem. 2006; 54 (10):1159-67.
22. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a defciency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491-502.
23. O'Brien FE, O'Connor RM, Clarke G, Dinan TG, Grifn BT, Cryan JF. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology. 2013;38(11):2209-19.
24. O'Brien FE, O'Connor RM, Clarke G, et al. Te P-glycoprotein inhibitor cyclosporin A diferentially infuences behavioural and neurochemical responses to the antidepressant escitalopram. Behav Brain Res. 2014;261:17-25.
25. Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci. 2010;30(4):1417-25.
26. Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 triggers an infammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol. 2006;70(3):1087-98.
27. Endicott JA, Ling V. Te biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137-71.
28. Morrow CS, Cowan KH, Frei E III. Drug resistance and its clinical circumvention. In: Holland J F, Bast RC, Morton DL, Kufe DW, Weichselbaum RR eds. Cancer Medicine. 4th ed. Baltimore, MD: Te Williams & Wilkins Co.; 1997:799-815.
29. Nicolazzo JA, Katneni K. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr Top Med Chem. 2009;9(2):130-47.
30. Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF. P-glycoprotein and breast cancer resistance protein infuence brain distribution of dasatinib. J Pharmacol Exp Ter. 2009;330(3):956-63.
31. Tian Q, Zhang J, Tan TM, et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res. 2005;22(11):1837-53.
32. Zlokovic BV. Te blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201.
33. Nordborg C, Sokrab TE, Johansson BB. Te relationship between plasma protein extravasation and remote Thissue changes after experimental brain infarction. Acta Neuropathol. 1991;82(2):118-26.
34. Wagner KR, Packard BA, Hall CL, et al. Protein oxidation and heme oxygenase-1 induction in porcine white matter following intracerebral infusions of whole blood or plasma. Dev Neurosci. 2002;24(2-3):154-60.
35. Ravindran J, Agrawal M, Gupta N, Rao PV. Alteration of blood brain barrier permeability by T-2 toxin: role of MMP-9 and infammatory cytokines. Toxicolog y. 2011;280(1-2):44-52.
36. Rosenberg GA, Estrada EY, Dencof JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. 1998;29(10):2189-95.
37. Yeung D, Manias JL, Stewart DJ, Nag S. Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown. Acta Neuropathol. 2008;115(6):635-42.
38. Haarmann A, Deiss A, Prochaska J, et al. Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown. PLoS One. 2010;5(10):e13568.
39. Eichler AF, Chung E, Kodack DP, Loefer JS, Fukumura D, Jain RK. Te biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344-56.
40. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Diferential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol. 1992;141(5): 1115-24.
41. Mudher A, Lovestone S. Alzheimer's disease-do tauists and bapThists fnally shake hands? Trends Neurosci. 2002;25(1):22-6.
42. Tiraboschi P, Hansen LA, Tal LJ, Corey-Bloom J. Te importance of neu-ritic plaques and tangles to the development and evolution of AD. Neurology. 2004;62(11):1984-9.
43. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35(11 suppl 1):2628-31.
44. Vogelgesang S, Jedlitschky G, Brenn A, Walker LC. Te role of the ATP-binding cassette transporter P-glycoprotein in the transport of beta-amyloid across the blood-brain barrier. Curr Pharm Des. 2011;17(26):2778-86.
45. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein defciency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115(11):3285-90.
46. Kovac A, Zilkova M, Deli MA, Zilka N, Novak M. Human truncated tau is using a diferent mechanism from amyloid-beta to damage the blood-brain barrier. J Alzheimers Dis. 2009;18(4):897-906.
47. Clark CM, Schneider JA, Bedell BJ, et al. Use of forbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-83.
48. Deo AK, Teil FP, Nicolas JM. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species diferences and effect of disease states. Mol Pharm. 2013;10(5):1581-95.
49. Friedman A. Blood-brain barrier dysfunction, status epilepticus, seizures, and epilepsy: a puzzle of a chicken and egg? Epilepsia. 2011;52(suppl 8):19-20.
50. Ghosh C, Gonzalez-Martinez J, Hossain M, et al. Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar fow. Epilepsia. 2010;51(8):1408-17.
51. Vautier S, Fernandez C. ABCB1: the role in Parkinson's disease and phar-macokinetics of antiparkinsonian drugs. Expert Opin Drug Metab Toxicol. 2009;5(11):1349-58.
52. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
53. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003;6(2):252-73.
54. Levin VA, Patlak CS, Landahl HD. Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm. 1980;8(3):257-96.
55. Trauble H. Te movement of molecules across lipid membranes: a molecular theory. J Membr Biol. 1971;4(1):193-208.
56. Seelig A, Seelig J. Te dynamic structure of fatty acyl chains in a phos-pholipid bilayer measured by deuterium magnetic resonance. Biochemistry. 1974;13(23):4839-45.
57. Durchschlag H, Zipper P. Calculation of the partial volume of organic compounds and polymers. Ultracentrifugation. 1994;94:20-39.
58. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ter. 2004;104(1):29-45.
59. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 1972;178(4064):984-6.
60. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2(4):541-53.
61. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999;16(10):1514-9.
62. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol. 1998;165(3):201-11.
63. Leeson PD, Davis AM. Time-related diferences in the physical property pro-fles of oral drugs. J Med Chem. 2004;47(25):6338-48.
64. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med. 2004;351(15):1548-63.
65. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol. 2002;64(9):1355-74.
66. Fehske KJ, Muller WE, Wollert U. Te location of drug binding sites in human serum albumin. Biochem Pharmacol. 1981;30(7):687-92.
67. Pardridge WM. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev. 1995;15(1-3):5-36.
68. Tsuji A, Tamai II. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 1999;36(2-3):277-90.
69. Pardridge WM, Oldendorf WH. Kinetics of blood-brain transport of hexoses. Biochim Biophys Acta. 1975;382(3):377-92.
70. Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta. 1975;401(1):128-36.
71. Pardridge WM. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res. 1998;23(5):635-44.
72. Pardridge WM. Peptide Drug Delivery to the Brain. New York, NY: Raven Press; 2001.
73. Yang C, Tirucherai GS, Mitra AK. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin Biol Ter. 2001;1(2):159-75.
74. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959-72.
75. Halmos T, Santarromana M, Antonakis K, Scherman D. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur J Pharmacol. 1996;318(2-3):477-84.
76. Gynther M, Ropponen J, Laine K, et al. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. J Med Chem. 2009;52(10):3348-53.
77. Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem. 1987;49(5):1651-8.
78. Vangilder RL, Rosen CL, Barr TL, Huber JD. Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ter. 2011;130(3):239-47.
79. Gynther M, Jalkanen A, Lehtonen M, et al. Brain uptake of ketoprofen-lysine prodrug in rats. Int J Pharm. 2010;399(1-2):121-8.
80. Parkinson FE, Damaraju VL, Graham K, et al. Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr Top Med Chem. 2011;11(8):948-72.
81. Paproski RJ, Wuest M, Jans HS, et al. Biodistribution and uptake of 3'-deoxy-3'-fuorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med. 2010;51(9):1447-55.
82. Oldendorf WH. Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids. Am J Physiol. 1973;224(6):1450-3.
83. Fischer W, Praetor K, Metzner L, Neubert RH, Brandsch M. Transport of val-proate at intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells: mechanism and substrate specifficity. Eur J Pharm Biopharm. 2008;70(2):486-92.
84. Part III. Blood-brain barrier transport techniques. In: Nag S, ed. Te Blood-Brain Barrier: Biology and Research Protocols. Totowa, NJ: Humana Press; 2003:193-304.
85. Pardridge WM, ed. Introduction to the Blood-Brain Barrier. Cambridge: Cambridge University Press; 1998.
86. Pardridge WM, Connor JD, Crawford IL. Permeability changes in the blood-brain barrier: causes and consequences. CRC Crit Rev Toxicol. 1975;3(2):159-99.
87. de Lange EC, Danhof M, de Boer AG, Breimer DD. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev. 1997;25(1): 27-49.
88. Tao R, Hjorth S. Diferences in the in vitro and in vivo 5-hydroxytryptamine extraction performance among three common microdialysis membranes. J Neu-rochem. 1992;59(5):1778-85.
89. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43(5):1369-74.
90. Geldenhuys WJ, Allen DD, Bloomquist JR. Novel models for assessing blood-brain barrier drug permeation. Expert Opin Drug Metab Toxicol. 2012;8(6):647-53.
91. Liu HL, Hua MY, Yang HW, et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci USA. 2010;107(34):15205-10.
92. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29(3):193-207.
93. Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci. 2006;27(6):310-6.
94. Kung HF, Kung MP, Choi SR. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med. 2003;33(1):2-13.
95. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ter. 2005;77(6):503-14.
96. Nakazawa S, Yokoyama C, Nishimura N, et al. Evaluation of dopamine D2/D3 and serotonin 5-HT2 A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography. Psychopharmacology (Berl). 2013;225(2):329-39.
97. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7):640-65.
98. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nano-scale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014;9:795-811.